Reversal or Repletion Treatment Strategies and Outcomes of Patients With Major Bleeding Events Managed in the Emergency Department: Large Real-Life Investigation in the Northwestern Healthcare District of Tuscany.
Alberto ContiMarco LeorinIrene Carlotta BogazziNoemi RenziGiuseppe PepeFabiana FrosiniLucilla FuresiLuca Dalla TomasinaPaolo PennatiLorenzo Ghiadoninull nullPublished in: Critical pathways in cardiology (2024)
Patients undergoing specific reversal therapy with on-label ADX or IDA, when treated with aFXa or aFII anticoagulants, respectively, showed statistically elevated differences in 30-day death compared with off-label repletion therapy with PCC. Overall, 30-day survival of patients on ongoing aFXa or aFII receiving on-label reversal therapy with ADX or IDA compared with off-label PCC repletion agents showed an increase of 71% and 30%, respectively.
Keyphrases
- emergency department
- healthcare
- patients undergoing
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- prognostic factors
- peritoneal dialysis
- type diabetes
- atrial fibrillation
- mesenchymal stem cells
- cell therapy
- bone marrow
- skeletal muscle
- patient reported outcomes
- smoking cessation
- patient reported
- electronic health record